Tarsus Pharmaceuticals Inc
TARS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.79B
Close$
$-40.00
158.1% downside
Current Fair Value
158.1% downsideOvervalued by 158.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.79 Billion |
|---|---|
| Enterprise Value | $2.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.59 |
| Beta | 0.5 |
| Outstanding Shares | 43,393,643 |
Return
| Return on Equity | -13.40% |
|---|---|
| Return on Assets | -7.60% |
| Return on Invested Capital | -8.83% |
Valuation & Multiples
| P/E Ratio | -59.44 |
|---|---|
| PEG | 675.81 |
| Price to Sales | 5.3 |
| Price to Book Ratio | 9.84 |
| Enterprise Value to Revenue | 4.26 |
| Enterprise Value to EBIT | -67.21 |
| Enterprise Value to Net Income | -56 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$169.65 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$183.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3030▼ 46.03% |
|---|---|
| Total Calls | 3,300▼ 98.79% |
| Total Puts | 1,000▼ 99.52% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 22.70%▼ 82.82% |
|---|---|
| Total Invested | $613.61M▼ 80.62% |
| Investors Holding | 90▼ 170.00% |
ESG Score
No data
About Tarsus Pharmaceuticals Inc
20 employeesTarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a num...